JP2022540000A5 - - Google Patents
Info
- Publication number
- JP2022540000A5 JP2022540000A5 JP2021576778A JP2021576778A JP2022540000A5 JP 2022540000 A5 JP2022540000 A5 JP 2022540000A5 JP 2021576778 A JP2021576778 A JP 2021576778A JP 2021576778 A JP2021576778 A JP 2021576778A JP 2022540000 A5 JP2022540000 A5 JP 2022540000A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- pharmaceutically acceptable
- acceptable salt
- fluoro
- carboxylic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962868057P | 2019-06-28 | 2019-06-28 | |
| US62/868,057 | 2019-06-28 | ||
| US202062960817P | 2020-01-14 | 2020-01-14 | |
| US62/960,817 | 2020-01-14 | ||
| US202063031719P | 2020-05-29 | 2020-05-29 | |
| US63/031,719 | 2020-05-29 | ||
| PCT/IB2020/056066 WO2020261205A1 (en) | 2019-06-28 | 2020-06-26 | Thieno[3,2-b]thiophene-2-carboxylic acid compounds having bckdk inhibiting activity |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022540000A JP2022540000A (ja) | 2022-09-14 |
| JP2022540000A5 true JP2022540000A5 (enExample) | 2023-06-02 |
Family
ID=71452516
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021576778A Pending JP2022540000A (ja) | 2019-06-28 | 2020-06-26 | Ｂｃｋｄｋ阻害活性を有するチエノ［３，２－ｂ］チオフェン－２－カルボン酸化合物 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US11542270B2 (enExample) |
| EP (1) | EP3990461A1 (enExample) |
| JP (1) | JP2022540000A (enExample) |
| CA (1) | CA3144869C (enExample) |
| PY (1) | PY2030111A (enExample) |
| TW (1) | TW202115086A (enExample) |
| UY (1) | UY38768A (enExample) |
| WO (1) | WO2020261205A1 (enExample) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202115086A (zh) * | 2019-06-28 | 2021-04-16 | 美商輝瑞大藥廠 | Bckdk抑制劑 |
| TW202228762A (zh) * | 2020-01-30 | 2022-08-01 | 美商美國禮來大藥廠 | 提派肽(tirzepatide)之治療用途 |
| US12569186B2 (en) | 2021-01-27 | 2026-03-10 | Koninklijke Philips N.V. | Apparatus and method for augmented interpretation of magnetic resonance and ultrasound shear wave elastography for monitoring liver fibrosis |
| WO2022175959A1 (en) * | 2021-02-21 | 2022-08-25 | Ramino-Bio | Thiophene based compounds and use thereof as bckdk inhibitors |
| EP4330665A1 (en) | 2021-04-26 | 2024-03-06 | Reprieve Cardiovascular, Inc. | Measuring and/or detecting analytes in urine, and associated systems, devices, and methods |
| US20230010793A1 (en) * | 2021-07-12 | 2023-01-12 | Reprieve Cardiovascular, Inc. | Fluid therapy based on estimated excess fluid, and associated systems and methods |
| IL312296A (en) * | 2021-12-01 | 2024-06-01 | Pfizer | 3-PHENYL-1-BENZOTHIOPEN-2-CARBOXYLIC ACID DERIVATIVES AS INHIBITORS OF BRANCHED ALPHA KETO ACID DEHYDROGENSIS KINASE FOR THE TREATMENT OF DIABETES, KIDNEY DISEASES, NASH AND HEART |
| CN114903994A (zh) * | 2022-04-19 | 2022-08-16 | 上海交通大学医学院附属瑞金医院 | Bckdk作为靶点在制备2型糖尿病药物中的应用 |
| CN121311466A (zh) | 2023-04-14 | 2026-01-09 | 辉瑞大药厂 | 葡萄糖依赖性促胰岛素多肽受体拮抗剂及其用途 |
| US12257416B1 (en) | 2023-09-12 | 2025-03-25 | Reprieve Cardiovascular, Inc. | Fluid therapy based on sodium excretion, and associated systems, devices, and methods |
| AU2025209211A1 (en) | 2024-01-18 | 2026-07-30 | Tuojie Biotech (Shanghai) Co., Ltd. | Pyridothiophene-2-carboxylic acid derivative, preparation method therefor and use thereof |
| TW202539633A (zh) | 2024-02-01 | 2025-10-16 | 美商輝瑞股份有限公司 | 葡萄糖依賴性促胰島素多肽受體拮抗劑及其用途 |
| US12582773B2 (en) | 2024-02-16 | 2026-03-24 | Reprieve Cardiovascular, Inc. | Urine output sensing without use of an indwelling catheter, and associated systems, devices, and methods |
| WO2025224599A1 (en) | 2024-04-22 | 2025-10-30 | Pfizer Inc. | Pyrrolidine-based glucose-dependent insulinotropic polypeptide receptor antagonists and uses thereof |
| WO2026013531A1 (en) | 2024-07-10 | 2026-01-15 | Pfizer Inc. | Spiro[2.5]octane compounds |
| WO2026033382A1 (en) | 2024-08-07 | 2026-02-12 | Pfizer Inc. | Heterocyclic glp-1r modulators |
| WO2026042018A1 (en) | 2024-08-21 | 2026-02-26 | Pfizer Inc. | 4-{4-[(1-{[4-(propan-2-yl)phenyl]carbamoyl)-d-prolyl)amino]cyclohexyl}benzoic acid derivatives as gipr antagonists for the treatment of diabetes |
| WO2026078617A1 (en) | 2024-10-11 | 2026-04-16 | Pfizer Inc. | Glucose-dependent insulinotropic polypeptide receptor antagonists and uses thereof |
| WO2026078672A1 (en) | 2024-10-13 | 2026-04-16 | Pfizer Inc. | Glucose-dependent insulinotropic polypeptide receptor antagonists and uses thereof |
| WO2026078673A1 (en) | 2024-10-13 | 2026-04-16 | Pfizer Inc. | Glucose-dependent insulinotropic polypeptide receptor antagonists and uses thereof |
| WO2026078671A1 (en) | 2024-10-13 | 2026-04-16 | Pfizer Inc. | Heterocyclic compounds as glucose-dependent insulinotropic polypeptide receptor antagonists |
| WO2026078674A1 (en) | 2024-10-13 | 2026-04-16 | Pfizer Inc. | Heterocyclic derivatives as glucose-dependent insulinotropic polypeptide receptor antagonists and uses thereof |
| WO2026078670A1 (en) | 2024-10-13 | 2026-04-16 | Pfizer Inc. | Heterocyclic derivatives as glucose-dependent insulinotropic polypeptide receptor antagonists |
| WO2026088071A1 (en) | 2024-10-23 | 2026-04-30 | Pfizer Inc. | Substituted fused heteroaryl lactam compounds |
| WO2026154417A1 (en) | 2025-01-17 | 2026-07-23 | Pfizer Inc. | Fused heterocyclic amide/sulfonamide compounds as agonists of the calcitonin/amylin receptors for the treatment of obesity |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| CA1146866A (en) | 1979-07-05 | 1983-05-24 | Yamanouchi Pharmaceutical Co. Ltd. | Process for the production of sustained release pharmaceutical composition of solid medical material |
| US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
| US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
| DE3438830A1 (de) | 1984-10-23 | 1986-04-30 | Rentschler Arzneimittel | Nifedipin enthaltende darreichungsform und verfahren zu ihrer herstellung |
| US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| ES2111065T5 (es) | 1991-04-16 | 2005-06-16 | Nippon Shinyaku Company, Limited | Procedimiento para producir una dispersion solida. |
| US5340591A (en) | 1992-01-24 | 1994-08-23 | Fujisawa Pharmaceutical Co., Ltd. | Method of producing a solid dispersion of the sparingly water-soluble drug, nilvadipine |
| JP3265680B2 (ja) | 1992-03-12 | 2002-03-11 | 大正製薬株式会社 | 経口製剤用組成物 |
| US5612359A (en) | 1994-08-26 | 1997-03-18 | Bristol-Myers Squibb Company | Substituted biphenyl isoxazole sulfonamides |
| DE19504832A1 (de) | 1995-02-14 | 1996-08-22 | Basf Ag | Feste Wirkstoff-Zubereitungen |
| TW536540B (en) | 1997-01-30 | 2003-06-11 | Bristol Myers Squibb Co | Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe |
| PT901786E (pt) | 1997-08-11 | 2007-08-07 | Pfizer Prod Inc | Disperções farmacêuticas sólidas com biodisponibilidade melhorada |
| ID26984A (id) | 1998-07-06 | 2001-02-22 | Bristol Myers Squibb Co | Senyawa-senyawa sulfonamida sebagai antagonis reseptor angiotensin endotelin ganda |
| DZ3347A1 (fr) | 2000-05-22 | 2001-11-29 | Aventis Pharma Inc | Dérivés d'arylméthylamine pour leur utilisation comme inhibiteurs de la tryptase |
| GB0012362D0 (en) * | 2000-05-22 | 2000-07-12 | Aventis Pharma Ltd | Chemical compounds |
| GB0021831D0 (en) * | 2000-09-06 | 2000-10-18 | Astrazeneca Ab | Chemical compounds |
| EA011086B9 (ru) | 2004-05-12 | 2012-08-30 | Пфайзер Продактс Инк. | Производные пролина и их применение в качестве ингибиторов дипептидилпептидазы iv |
| EP2010520B1 (en) | 2006-04-20 | 2012-09-12 | Pfizer Products Inc. | Heterobicyclic amides for the prevention and treatment of glucokinase-mediated diseases |
| KR20090024823A (ko) * | 2006-06-30 | 2009-03-09 | 세프라코 아이엔시. | Ｄ-아미노산 옥시다제의 융합된 헤테로사이클 억제제 |
| US20090036425A1 (en) | 2007-08-02 | 2009-02-05 | Pfizer Inc | Substituted bicyclolactam compounds |
| CA2729581A1 (en) | 2008-07-29 | 2010-02-04 | Pfizer Inc. | Fluorinated heteroaryls |
| ES2380408T3 (es) | 2008-08-28 | 2012-05-11 | Pfizer Inc. | Derivados de dioxa-biciclo[3.2.1]octano-2,3,4-triol |
| TW201038580A (en) | 2009-02-02 | 2010-11-01 | Pfizer | 4-amino-5-oxo-7,8-dihydropyrimido[5,4-f][1,4]oxazepin-6(5H)-yl)phenyl derivatives |
| WO2010103437A1 (en) | 2009-03-11 | 2010-09-16 | Pfizer Inc. | Benzofuranyl derivatives used as glucokinase inhibitors |
| EP2406230A1 (en) | 2009-03-11 | 2012-01-18 | Pfizer Inc. | Substituted indazole amides and their use as glucokinase activators |
| CA2754523A1 (en) | 2009-03-20 | 2010-09-23 | Pfizer Inc. | 3-oxa-7-azabicyclo[3.3.1]nonanes |
| CA2759843A1 (en) | 2009-05-08 | 2010-11-10 | Pfizer Inc. | Gpr 119 modulators |
| EP2427448A1 (en) | 2009-05-08 | 2012-03-14 | Pfizer Inc. | Gpr 119 modulators |
| GEP20135907B (en) | 2009-06-05 | 2013-08-12 | Pfizer | L-(piperidin-4-yl)-pyrazole derivatives as gpr 119 modulators |
| WO2011005611A1 (en) | 2009-07-09 | 2011-01-13 | Merck Sharp & Dohme Corp. | Neuromedin u receptor agonists and uses thereof |
| EP2954780A1 (en) | 2009-07-24 | 2015-12-16 | Baylor College Of Medicine | Methods of modulation of branched chain acids and uses thereof |
| US20120022116A1 (en) | 2010-07-20 | 2012-01-26 | Huayun Deng | Compositions and methods for the treatment of pathological condition(s) related to gpr35 and/or gpr35-herg complex |
| WO2018109607A1 (en) | 2016-12-16 | 2018-06-21 | Pfizer Inc. | Glp-1 receptor agonists and uses thereof |
| CA3062602A1 (en) | 2017-05-11 | 2018-11-15 | Bristol-Myers Squibb Company | Thienopyridines and benzothiophenes useful as irak4 inhibitors |
| TW202115086A (zh) * | 2019-06-28 | 2021-04-16 | 美商輝瑞大藥廠 | Bckdk抑制劑 |
-
2020
- 2020-06-24 TW TW109121446A patent/TW202115086A/zh unknown
- 2020-06-26 UY UY0001038768A patent/UY38768A/es not_active Application Discontinuation
- 2020-06-26 CA CA3144869A patent/CA3144869C/en active Active
- 2020-06-26 WO PCT/IB2020/056066 patent/WO2020261205A1/en not_active Ceased
- 2020-06-26 PY PY202002030111A patent/PY2030111A/es unknown
- 2020-06-26 EP EP20736441.5A patent/EP3990461A1/en active Pending
- 2020-06-26 US US16/912,828 patent/US11542270B2/en active Active
- 2020-06-26 JP JP2021576778A patent/JP2022540000A/ja active Pending
- 2020-10-23 US US17/078,257 patent/US11059833B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022538576A5 (enExample) | ||
| ES3025032T7 (en) | Carboxy-benzimidazole glp-1r modulating compounds | |
| US8569339B2 (en) | Soluble guanylate cyclase activators | |
| US10358416B2 (en) | Substituted pyrrolidines as G-protein coupled receptor 43 agonists | |
| CN101903356B (zh) | 4-(4-氰基-2-硫代芳基)二氢嘧啶酮和它们的使用 | |
| JP7217273B2 (ja) | ピリジンカルボニル誘導体およびｔｒｐｃ６阻害剤としてのその治療的使用 | |
| US9273029B2 (en) | Pyridine-and pyrazine derivatives | |
| US9150575B2 (en) | Piperidinylpyrazolopyridine derivative | |
| JP5301456B2 (ja) | ヘテロアリールオキシキナゾリン誘導体 | |
| HRP20230631T1 (hr) | Agonisti receptora glp-1 i njihova upotreba | |
| US20240294525A1 (en) | Compounds as glp-1 receptor agonists and uses thereof | |
| CN114728168A (zh) | 三唑氨基甲酸酯吡啶基磺酰胺作为lpa受体拮抗剂及其用途 | |
| US20100190980A1 (en) | Pyrazinamide compound | |
| JP2017515836A5 (enExample) | ||
| JP2020521730A5 (enExample) | ||
| US9340506B2 (en) | Acetamide derivatives as glucokinase activators, their process and medicinal applications | |
| JP2011502982A5 (enExample) | ||
| AU2015313829A1 (en) | Fused heterocyclic compounds as GPR120 agonists | |
| IL319486A (en) | HSD17B13 Inhibitors and/or Retarders | |
| CN111655700A (zh) | 作为饥饿素o-酰基转移酶(goat)抑制剂的苄基-、(吡啶-3-基)甲基-或(吡啶-4-基)甲基-取代的噁二唑并吡啶衍生物 | |
| JPWO2009081782A1 (ja) | Ｎ−ピラゾール−２−ピリジンカルボキサミド誘導体 | |
| TW202539631A (zh) | 使用葡萄糖依賴性促胰島素多肽受體拮抗劑化合物及glp-1受體促效劑化合物之組合療法 | |
| WO2012129967A1 (zh) | 新型胺基吡啶类化合物、其制备方法、包含此类化合物的药物组合物及其用途 | |
| JP2024505708A (ja) | 新規化合物 | |
| TW201039827A (en) | Indoline compound |